| Name | Title | Contact Details |
|---|
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
BioAssay Systems is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reliance Medical is a Mason, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAM™, the world`s first injectable hydrogel designed to provide long-lasting barrier contraception for men. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.
PureFlora was founded in 2012 by Tivon Sidorsky, MD after a family member’s severe case of C. difficile introduced him to the efficacy of fecal matter transplants (FMT) and the need for a standardized, sanitary, and labor reducing system by which to collect, process, and deliver fecal matter. Recognizing the tremendous opportunity for research and clinical applications for human gut microbiota and the elegant solution proposed by Dr. Sidorsky, veteran medical device executive William L. Mince joined forces with the inventor building the now-patented technology and team that is PureFlora.